269 related articles for article (PubMed ID: 12513801)
41. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H
J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186
[TBL] [Abstract][Full Text] [Related]
42. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
Fallarino F; Fields PE; Gajewski TF
J Exp Med; 1998 Jul; 188(1):205-10. PubMed ID: 9653097
[TBL] [Abstract][Full Text] [Related]
43. The role of the CD28 receptor during T cell responses to antigen.
Linsley PS; Ledbetter JA
Annu Rev Immunol; 1993; 11():191-212. PubMed ID: 8386518
[TBL] [Abstract][Full Text] [Related]
44. Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
Kosmaczewska A; Ciszak L; Boćko D; Frydecka I
Arch Immunol Ther Exp (Warsz); 2001; 49(1):39-46. PubMed ID: 11266089
[TBL] [Abstract][Full Text] [Related]
45. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
Kearney ER; Walunas TL; Karr RW; Morton PA; Loh DY; Bluestone JA; Jenkins MK
J Immunol; 1995 Aug; 155(3):1032-6. PubMed ID: 7543510
[TBL] [Abstract][Full Text] [Related]
46. A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7.
Wu Y; Guo Y; Liu Y
J Exp Med; 1993 Nov; 178(5):1789-93. PubMed ID: 8228824
[TBL] [Abstract][Full Text] [Related]
47. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
48. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
[TBL] [Abstract][Full Text] [Related]
49. Involvement of CD28/CTLA4-B7 costimulatory pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Rashid MM; Tosa N; Chikuma S; Hashimoto A; Uede T
J Vet Med Sci; 2000 Jan; 62(1):29-36. PubMed ID: 10676886
[TBL] [Abstract][Full Text] [Related]
50. [Regulation of T-cell activation by CD28 and CTLA-4].
Nagel T; Kalden JR; Manger B
Med Klin (Munich); 1998 Oct; 93(10):592-7. PubMed ID: 9849050
[TBL] [Abstract][Full Text] [Related]
51. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
52. When ligand becomes receptor--tolerance via B7 signaling on DCs.
Finger EB; Bluestone JA
Nat Immunol; 2002 Nov; 3(11):1056-7. PubMed ID: 12407416
[No Abstract] [Full Text] [Related]
53. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
Boussiotis VA; Freeman GJ; Gribben JG; Daley J; Gray G; Nadler LM
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11059-63. PubMed ID: 7504293
[TBL] [Abstract][Full Text] [Related]
54. Transplantation and the CD28/CTLA4/B7 pathway.
Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
[No Abstract] [Full Text] [Related]
55. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis.
Shao H; Woon MD; Nakamura S; Sohn JH; Morton PA; Bora NS; Kaplan HJ
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2016-21. PubMed ID: 11481266
[TBL] [Abstract][Full Text] [Related]
56. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P
Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
[TBL] [Abstract][Full Text] [Related]
57. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.
Guinan EC; Gribben JG; Boussiotis VA; Freeman GJ; Nadler LM
Blood; 1994 Nov; 84(10):3261-82. PubMed ID: 7524733
[TBL] [Abstract][Full Text] [Related]
58. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3'-kinase.
Stein PH; Fraser JD; Weiss A
Mol Cell Biol; 1994 May; 14(5):3392-402. PubMed ID: 8164687
[TBL] [Abstract][Full Text] [Related]
59. Regulation of T cell activation by CD28 and CTLA4.
Noel PJ; Boise LH; Thompson CB
Adv Exp Med Biol; 1996; 406():209-17. PubMed ID: 8910687
[TBL] [Abstract][Full Text] [Related]
60. The role of CTLA-4 in the regulation and initiation of T-cell responses.
Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
